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Obesity is a major contributor to the rising prevalence of cardiovascular and metabolic diseases in both the developed and 
developing world. Increased adipose tissue mass is associated with changes to the structure and function of the cardiovascular 
system to ensure circulatory requirements are met. Adipose tissue is a metabolically active endocrine organ that is capable of 
synthesizing and releasing a variety of signal proteins (adipokines), many of which impact unfavorably on both the cardiovascular 
system and metabolism. The extent of adiposity, location of fat deposits and variations in the secretion of adipokines, along with 
other factors, determine whether a particular obese person develops complications, including type 2 diabetes, coronary artery 
disease, congestive heart failure, hypertension, obstructive sleep apnea syndrome, and non-alcoholic fatty liver disease. This 
review will discuss the relationship between obesity and cardiovascular and metabolic diseases and will explore how complica-
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INTRODUCTION 
Obesity is a chronic condition characterized by the accumula-
tion of excess fat, to the extent that health may be adversely 
affected (1). It is a multifactorial disorder that develops via 
interaction between genetics and environment (2,3). In the 
modern western world, it is very easy to access large volumes 
of energy-dense foods at low cost and with minimal energy 
expended. When energy intake is greater than energy expendi-
ture, adipose tissue increases. With excess body weight comes 
the risk of long-term health consequences. Presently, all over-
weight and obese adults aged > 18 years and with a body mass 
index (BMI) ≥ 25 kg/m2 are considered at risk for developing 
one or more of the many comorbidities associated with obesity, 
such as hypertension, dyslipidemia, type 2 diabetes mellitus 
(T2DM), coronary heart disease (CHD), gallbladder disease, 
non-alcoholic fatty liver disease (NAFLD), stroke, osteoporo-
sis, obstructive sleep apnea, polycystic ovary syndrome, and 
some types of cancers (1). 
This review will address these complications and the as-
sociations between cardiovascular disease (CVD) and obesity 
and the impact of excess body weight on overall morbidity 
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and mortality (4), such that life expectancy is greatly reduced 
in obesity (5). 
PREVALENCE OF OBESITY 
The latest report from The Centers for Disease Control and 
Prevention in the United States shows the prevalence of obes-
ity continues to increase (6). In 1991, four States had obesity 
prevalence rates of 15–19 % and no States had rates at or above 
20 %. Over the past 15 years, there has been a steady increase, 
such that in 2005 only 4 States had obesity prevalence rates 
less than 20 %, while 17 States had prevalence rates equal to 
or greater than 25 percent, with 3 of those having prevalence 
equal to or greater than 30 %. This trend is being observed in 
other developed and developing countries in adults (1, 7-9), 
children and adolescents (10-13). The Aus-Diab study reported 
that the prevalence of obesity in Australian adults was 2.5 
times higher in the year 2000 than in 1980 (9). A large cohort 
study of over 64,000 Finnish adolescents reported that the 
prevalence of overweight increased from 7.2 to 16.7% in boys 
and from 4.0 to 9.8%, in girls between 1977 and 1999, while 
the prevalence of obesity increased 3 fold (13). 
Impact of obesity on the prevalence of cardiovascular 
disease-related mortality
While the incidence of obesity has expanded dramatically in 
the past 2 decades, so has the number of deaths associated with 
the condition. Data from five large prospective cohort studies
have been used to calculate the annual number of deaths at-
tributable to obesity in adults in 1991 (14). The authors found 
that 80% of deaths attributable to obesity occurred in people 
with a BMI > 30 kg/m2. However, a number of limitations are 
encountered in this meta-analysis. Data were collected from 
a predominantly Caucasian population, half of the studies in-
cluded self-reported body weight data, the statistical analysis 
model considered only age, smoking and sex and the outcomes 
were not assessed after 1991. Flegal et al (15) reported that the 
relative risk of mortality associated with obesity with a BMI > 
35 kg/m2 was twice that of a healthy weight individual, with 
influence diminishing in the elderly (age > 70 years). Of note,
mortality related to obesity has declined since the first National
Health and Nutrition Examination Survey (NHANES) study 
in 1971 (15), a result most likely due to a more aggressive 
approach to the treatment of associated CVD risk factors in 
obese patients. 
In a recent analysis by Yan et al, baseline measurements 
of BMI were recorded before the age of 65 years in 17,643 
subjects from the Chicago Heart Study, free of CHD and 
diabetes (16). The outcome of death from CHD, CVD or dia-
betes after the age of 65 years was adjusted for hypertension, 
hypercholesterolemia and cigarette smoking. At a low level of 
risk, obesity had very little impact on CVD outcomes but did 
impact on the relative risk of diabetes, but for obese subjects 
at moderate risk there was a two-fold increased risk of CHD 
mortality and a 5-fold increase risk for diabetes. Overall, these 
data suggest that obese subjects during midlife have a greater 
likelihood of mortality from CHD after the age of 65 years, 
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independent of the presence of hypertension, hypercholeste-
rolemia and cigarette smoking.
Age of onset of obesity: what are the implications for 
morbidity and mortality?
Early-onset obesity in children is also a risk factor for morbi-
dity and mortality later in life (17,18) and approximately 70% 
of obese adolescents grow up to become obese adults (19). 
Although the persistence of excess adiposity from childhood 
to adulthood is a morbidity risk factor, it is unclear whether 
total body fat or body fat distribution is the main factor re-
sponsible (18). Obesity is also associated with the metabolic 
syndrome in adolescents (20). The SEARCH for Diabetes in 
Youth Study (a multicentred trial conducted across 6 States of 
the USA) reported that children and adolescents with diabetes 
may be at significant increased risk of premature CVD, since
the prevalence of multiple CVD risk factors was high among 
children and adolescents with diabetes, including children 
as young as 3 years (21). If elevated blood pressure (BP) is 
also present in childhood or adolescent obesity then there is 
an increased risk of hypertension in adulthood, with central 
adiposity influencing the extent of elevation (22). However,
the way in which obesity is determined impacts on whether 
there is an association between obesity in early life and track-
ing into adulthood. Wright et al (23) reported on 412 members 
of the thousand families 1947 birth cohort, from Newcastle in 
the UK. They found an association between BMI at age 9, 13 
and 50 such that those who had been above the 90th percentile 
for BMI at age 9 or 13 years were between five and nine times
more likely to be obese (BMI > 30) as adults (age 50) when 
compared with those in the thinnest quartile in childhood. 
However, when percent body fat was measured at age 50 
using bioelectrical impedance, the association with BMI in 
childhood was no longer significant. Another important find-
ing from this study was that those who were thin in childhood 
and adolescence were not protected from obesity as adults, 
which is an important public health message. 
CARDIORESPIRATORY FITNESS AND CARDIOVASCULAR 
RISKS 
An important parameter often overlooked in outcome studies in 
overweight and obese subjects is the level of physical activity. 
Low levels of fitness are associated with an increased preva-
lence of CVD risk factors (24) and the level of physical activity 
is a predictor of CHD, independent of the presence of obesity 
(25). Previous findings suggest that even light-to-moderate
activity is associated with lower CHD rates in women, with as 
little as 1 hour of walking per week associated with a reduc-
tion in risk. It was encouraging to note from this study that the 
intensity of exercise did not dictate the benefit gained (26). In
women with established CHD, higher self-reported physical 
fitness scores were independently associated with fewer risk
factors for coronary artery disease (CAD), less angiographic 
CAD, and lower risk for adverse cardiovascular events (27). 
These studies promote an increase in physical activity for 
cardiovascular and metabolic health, not just to assist with 
weight loss. It should also be noted that cardiorespiratory fit-
ness is inversely associated with the prevalence of metabolic 
syndrome (28) and those at risk of developing this condition 
should be encouraged to increase their physical activity from 
an early age, since poor fitness in young adults is associated
with the development of cardiovascular complications (29) 
CARDIOVASCULAR RISKS ASSOCIATED WITH OBESITY 
The association between overweight/obesity and CVD risk 
has been known for many years, with evidence from several 
large cohort studies (30-32). After 44 years of follow-up of 
the Framingham Heart Study, Wilson et al (33) showed that 
risk of CVD (including angina, myocardial infarction, CHD, 
or stroke) was higher among overweight men (relative risk 
(RR) 1.24; 95% confidence interval (CI): 1.07–1.44), obese 
men (RR 1.38; 95% CI: 1.12–1.69) and obese women (RR 
1.38; 95% CI: 1.14–1.68) after adjustment for age, smoking, 
high blood pressure, high cholesterol and diabetes. During a 
14 year follow up of 1 million adults in the United States, it 
was found, as BMI increased, that there was an increase in the 
risk of death from all causes, CVD, cancer or other diseases 
for both men and women in all age groups (34). These findings
confirmed the previous report of the Nurses’ Health Study (35). 
In the Nurses’ Health Study, weight gain of 5-8 kg increased 
CHD risk (non fatal myocardial infarction and CHD death) 
by 25%, and weight gain of ≥ 20 kg increased risk more than 
2.5 times in comparison with women whose weight was stable 
within a range of 5 kg (36). In British men, an increase of 1 
BMI unit was associated with a 10% increase in the rate of 
coronary events (37). 
The Lancet recently published a systematic review of cohort 
studies assessing the association between body weight, total 
mortality and CAD (38). This review pooled data from 40 
studies which included over 250,000 patients and concluded 
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that being overweight or mildly obese gave better outcomes for 
cardiovascular and total mortality than being in the standard 
healthy BMI range. Patients with severe obesity (BMI > 35 
kg/m2) had the highest risk for cardiovascular mortality (RR 
1.88, 95% CI 1.05-3.34). This outcome suggests that perhaps 
using percent body fat may be more appropriate than BMI 
as the indicator of obesity. Another important consideration 
with this review is that the studies includes only had follow-
up for up to 3-8 years, which is insufficient to detect the full
effect of being overweight on CAD progression and long-term 
outcomes. It has been suggested that in fact the full effect of 
obesity on cardiovascular mortality may only be seen after 15 
years or more (39). Thompson et al (40) conducted a follow up 
study in men and reported that the lifetime risk of CHD was 
significantly higher in severely obese men (BMI of 37.5 kg/
m2= 46.4% risk) compared with 34.9% for lean me of similar 
age (BMI of 22.5 kg/m2). This risk was substantially reduced 
with sustained moderate weight loss (10%) and would yield 
substantial health and economic benefits (41).
Degree of adiposity and risk of cardiovascular dis-
ease
Data from 115,886 women in the Nurses’ Health Study showed 
that even mild-to-moderate overweight (BMI = 25.0–28.9 
kg/m2) increased the risk of nonfatal CHD in middle-aged 
women after adjustment for age and smoking (RR 1.8; 95% 
CI: 1.2–2.5). Among those with a BMI ≥ 29 kg/m2, the risk 
increased more than 3 folds (RR 3.3; 95% CI: 2.3–4.5). The 
effect was substantially reduced after adjusting for other CVD 
risk factors, but remained significant among those with a BMI
≥ 29 kg/m2 (RR 1.9; 95% CI: 1.3–2.6) (42). Willett et al (36) 
concluded that higher levels of body weight within the ‘nor-
mal’ range, as well as modest weight gain (more than 5 kg) after 
18 years of age, appear to increase risks of CHD in middle-aged 
women. After controlling for age, smoking, menopausal status, 
hormone replacement therapy and parental history of CHD, 
significant increases in risk were still observed among those
with a BMI ≥ 23 kg/m2 compared with those with a BMI < 
21 kg/m2. The RRs for CHD were 1.5 (95% CI: 1.2–1.8) for 
a BMI = 23.0–24.9 kg/m2, 2.1 (95% CI: 1.7–2.5) for a BMI 
= 25.0–28.9 kg/m2 and 3.6 (95% CI: 3.0–4.3) for a BMI ≥ 29 
kg/m2. However, significant weight gain during adulthood
(range: 20–34.9 kg) approximately doubled the coronary risk 
after controlling for initial relative weight level at age 18 years 
(RR 2.5; 95% CI: 1.7–3.7). In contrast to weight gain through-
out life, ‘morbid obesity’ (defined as BMI ≥ 40 kg/m2) early 
in adult life is emerging as a significant risk factor for CHD
mortality, the duration of morbid obesity being the strongest 
predictor of chronic heart failure (CHF) (43).
Method of determining obesity impacts  
of cardiovascular risk
There is strong debate as to which anthropometric measure is 
the best technique to assess the risk of CVD (44-47). Both BMI 
and waist-hip ratio (WHR) have been found to be independent 
risk factors for CHD and mortality irrespective of the presence 
of other coronary risk factors (44).Waist circumference (48) 
is strongly correlated with abdominal fat content and is the 
easiest way to assess a patient’s abdominal fat (49). The Health 
Professionals Follow-up Study found that waist circumference 
but not BMI predicted risk of death from CVD (50). However, 
the waist circumference cutoffs lose their incremental predic-
tive power in patients with a ≥ BMI 35 kg/m2 (51). Evidence 
from the Heart Outcomes Prevention Evaluation (HOPE) 
study of over 8,000 patients with stable CVD suggests that 
elevated waist circumference was significantly associated
with an increased risk of myocardial infarction (RR 1.23, P 
< 0.01), heart failure (RR 1.38, P < 0.03), and total mortal-
ity (RR 1.17, P < 0.05) (52). This supports previous findings
from the Framingham Study (53) which reported that the risk 
of CVD incidence and mortality increased with the degree of 
regional, central or abdominal obesity. Furthermore, when a 
group of low-risk, middle aged men were followed over 7.5 
years, having a higher waist circumference in association with 
elevated triglyceride levels increased the risk associated with 
CVD compared to those with the lowest waist circumference 
and triglyceride levels (RR 2.13; 95% CI: 1.21-3.76) (54).
Location of body fat
In humans and most animal models the development of obes-
ity leads not only to increased fat depots in classical adipose 
tissue locations but also to significant lipid deposits within
and around other tissues and organs, a phenomenon known 
as ectopic fat storage (55). Cardiac fat depots within and 
around the heart impair both systolic and diastolic functions, 
and may in the long-term promote CHF (56). Accumulation 
of fat around blood vessels (perivascular adipose tissue) may 
affect vascular function in a paracrine manner, as perivascular 
adipose tissue cells secrete vascular tone modulating factors, 
pro-atherogenic cytokines and smooth muscle cell growth 
93
Biomed Rev 17, 2006
Adipose tissue and heart health
factors (57). Furthermore, high amounts of perivascular fat 
could mechanically contribute to the increased vascular stiff-
ness seen after years of obesity (55).
The relative excess of fat in the abdomen aids in the devel-
opment of diabetes and atherosclerosis (58). The distribution of 
fat depots in the body is a strong independent predictor of CHD 
(52, 59, 60). Indeed, disturbances in lipoprotein metabolism, 
glucose homeostasis and hypertension have been reported 
in subjects with an excessive deposition of adipose tissue in 
the abdomen (59, 61-63). In addition, abdominal distribu-
tion of body fat is associated with increased plasma levels of 
fibrinogen and other factors that modulate coagulation, such
as plasminogen activator inhibitor-1 (PAI-1) and tissue factor. 
These same molecules may also contribute to left ventricular 
dysfunction (64).
STRUCTURAL AND METABOLIC CHANGES IN OBESITY AND 
IMPACT ON CARDIOVASCULAR RISKS
Excess adipose tissue results in a number of structural and 
functional adaptations by the cardiovascular system. With pro-
gressive and central accumulations of body fat, many cardiac 
complications often follow (65). The mechanisms involved 
are discussed in more detail in the next section.
Cardiovascular structure and function
Obesity is associated with abnormalities in cardiac structure 
and function (66-68) which can often be alleviated by weight 
loss. As there is an increased energy requirement to move 
excess body weight at any given level of activity, the cardiac 
workload is greater for obese subjects than for non-obese in-
dividuals (68). Thus, obese subjects are known to have higher 
cardiac output (CO) and a lower total peripheral resistance in 
the absence of hypertension (23). The high CO is attributable 
to increased stroke volume, while heart rate (HR) is usually 
unchanged (24). The increase in blood volume and CO in 
obesity is in proportion to the amount of excess body weight 
(69). Recent evidence from the HyperGen study shows that 
both increased total fat mass and fat-free mass are able to cause 
these physiological changes, although centrally located adipose 
tissue is particularly strongly associated with increased CO 
(70). In moderate to severe cases of obesity, an increased CO 
may lead to left ventricular dilatation, increased left ventricular 
wall stress, compensatory (eccentric) left ventricular hyper-
trophy (71-73) and left ventricular diastolic dysfunction (74). 
It is important to emphasize that left ventricular hypertrophy 
is an important risk factor for CHF. 
These complications from obesity occur irrespective of 
age. It has been reported in children as young as 12 years 
that obesity impairs the ability to exercise, elevates BP and 
increases left ventricular mass (LVM), indicating the devel-
opment of early cardiovascular adaptation/damage in young 
individuals (75). In fact, the P-DAY Study in young men aged 
15 to 34 years demonstrated an accelerated progression of 
atherosclerosis at autopsy in obese individuals (76). Higher 
LVM and left ventricular dysfunction have been documented 
with longer duration of obesity (74). As previously mentioned, 
weight loss is able to diminish some of these anatomical and 
pathophysiological adaptations, including increased LVM (77) 
and abnormal ventricular filling (78, 79).
Obesity is associated with changes in the parasympathetic 
regulation of the heart. This is reflected by impairment of heart
rate recovery (HRR) following exercise (80), which is an inde-
pendent risk factor for CVD and mortality (81). Brinkworth et 
al (82) investigated HRR in obese men and women free from 
CVD but with a range of metabolic complications before and 
after 12 weeks of weight loss. There was a significant improve-
ment in HRR but no change in cardiorespiratory fitness. In this
study the improvement in HRR was also associated with a 
reduction in blood glucose, supporting exercise as an important 
strategy to improve metabolic pathway regulation.
Metabolic complications
It has been hypothesized that the insulin resistance associated 
with obesity may in fact be a protective/adaptive mechanism 
against further weight gain (83). For many years adipose tissue 
was considered a passive lipid storage organ. However it is 
now clear that adipose tissue plays an active role in controlling 
not only lipid and energy homeostasis but also other biological 
processes, such as feeding behavior, inflammation, immunity,
hemostasis, angiogenesis, and reproduction (84-88). The 
metabolic alterations of adipose tissue that occur in obesity 
are numerous. These associate with an increased adipose tis-
sue endo- and paracrine secretion of signal proteins, including 
growth factors, renin/angiotensin and related molecules, chem-
okines, and pro- and anti-inflammatory cytokines, collectively
named adipokines (84-86). 
ADIPOKINES AND CARDIOVASCULAR AND METABOLIC 
DISEASES
Today, the list of adipokines include more than 100 proteins 
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such as leptin, adiponectin, visfatin, omentin, tumor necrosis 
factor-alpha (TNF-α), interleukin-1 (IL-1), IL-6, IL-10, IL-18, 
IL-1 receptor antagonist, IL-8 and other chemokines as well as 
transforming growth factor-β1 (TGF-β1), nerve growth factor 
(NGF) and other growth factors (84-88). The classic cytokines, 
TNF-α and interleukins, within adipose tissue originate pre-
dominantly from in situ macrophages (89-91) and possibly 
mast cells (84) but also from adipocytes and nonfat cells of the 
adipose tissue (92). The altered production of these molecules 
has characterized obesity as a state of chronic, low-grade 
inflammation (93), which may contribute to the development
of insulin resistance and endothelial dysfunction (94-96) and 
the pathophysiology of CVD (63). 
The overproduction of adipokines in obesity contributes to 
physiological changes in cardiac function. Changes in adipose 
tissue production of TGF-β1 may be a potential pathophysi-
ological mechanism for development of left ventricular fill-
ing abnormalities in obesity-associated hypertension (97). A 
relative deficiency of adiponectin may promote inflammation
and vascular dysfunction by a reduced ability to inhibit local 
proinflammatory signals and prevent plaque formation (98).
Proatherogenic chemokines, such as monocyte chemoattractant 
protein 1 (MCP-1, also named CCL2, cysteine-cysteine motif 
chemokine ligand 2) and IL-8 (CXCL8), are also elevated 
in obesity. Such molecules may modulate the migration of 
granulocytes and monocytes into the arterial wall (57). Increased 
MCP-1 is associated with a number of alterations in the cardiac 
system, including increased LVM and altered diastolic filling
(99). Persistent inflammation has been associated with CHF by
reducing cardiac contractility, inducing cardiac hypertrophy and 
promoting apoptosis, a process that contributes to undesirable 
myocardial remodeling (100).
Metabolic syndrome
The term "metabolic syndrome" refers to a cluster of specific
cardiovascular risk factors in one individual, its underlying 
pathophysiology being insulin resistance (4). Although several 
sets of diagnostic criteria exist such as those provided by the 
World Health Organization (101), National Cholesterol Edu-
cation Program (102), and the International Diabetes Federa-
tion (103, 104)), waist circumference, dyslipidemia, elevated 
blood pressure and glucose intolerance are shared by all. Data 
from NHANES in 1988-1992 and 1999-2000 revealed that 
the prevalence of metabolic syndrome in adolescents aged 
12–19 years increased from 4.2% to 6.4% over a decade (105). 
Evidence from the DESIR participants in France revealed 
that, over a 6 year follow up period, a weight gain of greater 
than 9 kg was associated with a 21% incidence of metabolic 
syndrome (106). For every kilogram gained over the 6 years, 
the risk of developing metabolic syndrome increased by 22%. 
Uncertainty about the mechanism of pathogenesis has resulted 
in a debate to determine whether the metabolic syndrome is 
indeed a syndrome or an independent CVD risk factor (107). 
The next section describes the impact of obesity on each of 
these conditions. 
Atherosclerosis and coronary artery disease 
Increased adiposity is associated with greater risk of athero-
sclerosis, which leads to coronary artery calcification and the
development of CHD. Evidence from the Bogalusa Heart 
Study found that carotid intimal-medial thickness (IMT) at age 
35 years was correlated with BMI measured throughout life 
(108). The Muscatine Study (109) also found that increased 
adipose tissue in youth was correlated with an increase in 
coronary artery calcification and that this association was
stronger in males. The associations between obesity and the 
development of atherosclerotic lesions, as evidenced by fatty 
streaks and/or fibrous plaque lesions, is of particular concern
when damage is seen in young adults (110). 
A cross-sectional study by Takami et al (111) of 849 Japanese 
men aged 20–78 years investigated the relationship between 
body fatness (particularly abdominal fat) and carotid athero-
sclerosis. They found that general adiposity (as measured by 
BMI), waist circumference, WHR, abdominal subcutaneous 
fat and intra-abdominal fat were all correlated with carotid 
IMT after adjustment for age and smoking habit. Adjustment 
for BMI eliminated all other associations except the ones with 
WHR with IMT, suggesting that in this population abdominal 
fat is not as strongly associated with carotid atherosclerosis as 
is general body fatness. The Progetto ATENA study is a large 
(over 5,000 participants) ongoing investigation of the causes of 
CVD and cancer in Italian females aged 30 to 69 years. Within 
that study, De Michele et al (112) reported on a sub-sample of 
310 women and concluded that BMI and WHR were signifi-
cant predictors of carotid wall thickness independent of other 
cardiovascular risk factors (age, BP, lipid abnormalities, and 
fasting insulin). As BMI increased, IMT increased along with 
other coronary risk factors, including systolic blood pressure 
(SBP), diastolic blood pressure (DBP), triglycerides (TG), 
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fasting glucose, insulin, and lower high-density lipoprotein 
(HDL)-cholesterol concentrations.
Obesity may be an independent risk factor for ischemic 
heart disease. However, numerous studies have been unable 
to confirm this association because of the short time period
of observation. Indeed, the association between obesity and 
ischemic heart disease seems evident only after 2 decades 
of follow-up (32). The Manitoba Heart Study reported that 
a high BMI was significantly associated with development
of myocardial infarction, coronary insufficiency and sudden
death (32). 
Hypertension
The majority of patients with high BP are overweight and 
hypertension is about 6 times more frequent in obese than lean 
subjects (113). This represents an estimated 12 % increased 
risk for CHD and 24 % increased risk for stroke (51). The as-
sociation between obesity and hypertension begins in early life. 
Longitudinal observations of children, adolescents and young 
adults enrolled in the Bogalusa Heart Study show that obesity 
persists over time and is linked to the commonly clustered 
components of metabolic syndrome, including hypertension, 
hyperinsulinemia/insulin resistance and dyslipidemia, which 
in turn is associated with the processes leading to CVD (114). 
The INTERSALT Study, based on more than 10,000 people 
from 52 centers and 32 countries around the world reported a 
significant and independent relationship between high BP and
increased BMI in more than 90% of all participants (89,115). 
Irrespective of age, for every BMI unit increase, there was an 
associated increase in SBP of 0.91 mmHg for men and a 0.72 
mmHg increase for women. For DBP, this increase was 0.75 
mmHg for men and 0.5 mmHg for women per BMI unit (89, 
115). Overall, a 10-kilogram increase in body weight was 
associated with an elevation of 3.0 mmHg in SBP and a 2.2 
mmHg in DBP (89).
While the association between obesity and hypertension is 
well recognised, the underlying pathophysiological mecha-
nisms are still poorly understood. The expansion of extracellu-
lar volume and increased CO are characteristic haemodynamic 
changes that occur with obesity-related hypertension (94). A 
variety of endocrine, genetic, and metabolic mechanisms have 
also been linked to the development of obesity hypertension 
(63, 65, 116-118). One potential mechanism leading to the 
development of obesity-induced hypertension may be through 
leptin-mediated sympatho-activation (119). Recently devel-
oped strains of spontaneously hypertensive rats with obesity 
may be a promising experimental target for further studies on 
obesity-related hypertension, although this should be done 
with caution since the original spontaneously hypertensive 
rat strain were on a different background and hence the type 
of hypertension these new rats have developed may have a 
different pathophysiology (120). 
The Framingham Heart Study reported that obesity was sig-
nificantly correlated with increased LVM (121) and it has been
shown that a 10% reduction in weight of obese hypertensive 
patients not only reduced blood pressure, but also decreased 
left ventricular wall thickness and LVM (77). There is evidence 
in both overweight hypertensive and non-hypertensive patients 
that weight loss produced by lifestyle modifications reduces
BP levels (122). Weight reduction is one of the rare anti-hyper-
tensive strategies that decreases BP in normotensive as well as 
hypertensive individuals (51). However, this reduction is not 
always maintained once weight is stable (123) and it has been 
suggested that the extent to which BP decreases is influenced
by several factors, including the duration of hypertension (124) 
and the composition of the diet (125).
The reduction in BP could also be attributable to (i) reduc-
tions in salt intake concomitant with caloric restriction (122) 
or (ii) reductions in total circulating and cardiopulmonary 
blood volume, as well as (iii) reductions in sympathetic nerv-
ous system activity (97). The reduction in plasma catecho-
lamines and plasma renin activity, which are associated with 




Dyslipidemia (reduced levels of HDL-cholesterol and elevated 
apolipoprotein B levels and a prevalence of LDL particles) is 
commonly found in obesity (126) with central adiposity associ-
ated with CHD (74). A BMI change of 1 unit is associated with 
a decrement change in HDL-cholesterol of 1.1 mg/dl for young 
adult men and 0.69 mg/dl for young adult women (2). There is 
evidence that weight loss achieved by lifestyle modification in
overweight individuals is accompanied by a reduction in serum 
TG and an increase in HDL-cholesterol (86). Weight loss may 
also contribute to a reduction in serum total cholesterol and 
LDL-cholesterol levels (87). Moreover, in subjects with type 
2 diabetes, aerobic exercise may mediate an improvement in 
the lipid profiles through fat loss (127-132).
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Type 2 diabetes mellitus 
Several prospective studies in numerous countries have 
demonstrated an elevated risk of diabetes mellitus as weight 
increases (75-77). The development of T2DM is associated 
with weight gain after age 18 years in both men and women, 
such that the relative risk of diabetes increases by approxi-
mately 25 % for each additional unit of BMI over 22 kg/m2 
(133). Moreover cross-sectional and longitudinal studies show 
that abdominal obesity is a major risk factor for T2DM (30, 
102, 116). 
There is strong evidence that weight loss reduces blood glu-
cose levels and hemoglobin A1c levels in patients with T2DM. 
Moreover, in three European cohorts (> 17,000 men) followed 
for over 20 years, non-diabetic men with higher blood glucose 
had a significantly higher risk of cardiovascular and CHD death
(134). In addition, it has been demonstrated in the Framingham 
Offspring Cohort that metabolic factors associated with obes-
ity (overall and central) including hypertension, low levels of 
HDL-cholesterol, increased levels of TG and insulin worsen 
continuously across the spectrum of glucose tolerance (135). 
Although BMI increased steadily with increasing glucose 
intolerance, the association between most other measures 
of metabolic risk and glycemia were independent of overall 
obesity and the gradient of increasing risk was similar for 
non-obese and obese participants (135). Thus, asymptomatic 
glucose intolerance is not a benign metabolic condition and 
characteristics associated with the insulin resistance syndrome 
should be taken seriously. This is further reinforced by the 
Quebec Cardiovascular Study, where hyperinsulinemia was 
reported as an independent risk factor for CHD (136). 
Non-alcoholic fatty liver disease 
Another metabolic adaptation that occurs with central obesity 
is non-alcoholic fatty liver disease (NAFLD. In this condition 
there is an increase in peripheral free fatty acid flux (mainly
derived from abdominal visceral fat depots) and de novo lipo-
genesis in the liver, which results in accumulation of hepatic 
fat. The occurrence of NAFLD increases with waist girth such 
that it is present in over 70 % of people with obesity or T2DM 
(137). In a prospective nested case control study in 2,103 type 
2 diabetic patients, Targher et al (138) found that NAFLD was 
significantly associated with an increased risk of CVD and
overall mortality, independent of classical risk factors and only 
partly explained by the occurrence of metabolic syndrome. 
Non-alcoholic fatty liver disease is positively associated with 
thickening of the carotid artery wall in patients with T2DM 
(139) and also associated with endothelial dysfunction inde-
pendent of obesity (140). Further, NAFLD is associated with 
increased levels of proinflammatory cytokines and markers
of oxidative stress as seen with many complications of obes-
ity. Musso et al (141) found that the histological severity of 
NAFLD was inversely correlated with circulating adiponectin 
levels independent of abdominal obesity and other metabolic 
syndrome components. The expression of adiponectin and 
adiponectin receptor II in the liver are also reduced in NAFLD 
rodent models (142). This supports previous reports that hy-
poadiponectinemia was closely related to hepatic fat content 
in diabetic patients (143) and that adiponectin delivery can 
alleviate steatosis and liver injury in animal models of fatty 
liver disease. The mechanisms behind adiponectin protection 
include modulation of TNF-α secretion/activity (144, 145), 
induction of hepatic fatty acid oxidation and inhibition of 
fatty acid synthesis (146). The question has been raised as to 
whether NAFLD contributes towards metabolic and cardio-
vascular complications or whether metabolic syndrome is the 
instigator of NAFLD. 
Obstructive sleep apnea syndrome 
Obstructive sleep apnea syndrome (OSAS) is one of the many 
respiratory complications associated with obesity. It is defined
as repeated episodes of obstructive apnea and hypopnea during 
sleep in association with altered cardiopulmonary function 
(147). Evidence is emerging that patients with apneic events 
that occur during sleep have associated acute and chronic 
hemodynamic changes during waking time, including el-
evated sympathetic tone, decreased stroke volume (SV) and 
CO, increased HR, and changes in circulating hormones that 
regulate BP, fluid volume, vasoconstriction and vasodilation
(148, 149). Weight loss is an effective method for reducing 
the extent of OSAS (150) and associated disruptive symptoms 
such as habitual snoring and daytime sleepiness (151).
Obstructive sleep apnea syndrome is thought to be both 
a systemic and local inflammatory condition (152). Inflam-
matory processes associated with OSAS may contribute to 
cardiovascular morbidity. Indeed, it is the presence of systemic 
inflammation, characterized by elevated levels of certain pro-
inflammatory mediators, such as C-reactive protein (153),
leptin (154), TNF-α, IL-1β, IL-6 (66), reactive oxygen spe-
cies and adhesion molecules, that may predispose people to 
the development of cardiovascular complications observed in 
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Figure 1. There is a complex interaction between the conditions that cluster to influence risk of cardiovascular disease, obesity
appearing to be central to the problem.  
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patients with OSAS. Interestingly, both TNF-α and IL-6 have 
been found to be significantly elevated in OSAS independent of
obesity (155). To date it is unclear how the cytokines directly 
mediate OSAS (156).
WEIGHT LOSS: IS IT POSSIBLE TO REVERSE THE DAMAGE? 
In 1998, the American Heart Association added obesity to its 
list of major modifiable risk factors for CHD (157). Although 
obesity is modifiable, the prevalence rates continue to increase
and weight reduction is difficult to achieve and even harder to
maintain, in part due to homeostatic mechanisms protecting 
against loss of nutrient stores (158, 159). Moreover, following 
weight loss, resumption of the obese state typically occurs, 
with fewer than 5 % of subjects remaining lean for more than 
four years (160). Loss of greater than 10 kg has previously 
been reported to have multiple benefits (161) but should be
done in consultation with a medical professional since it can 
have cardiovascular complications, depending on the rate of 
weight loss (65). Incorporating exercise to help achieve weight 
loss is important to ensure lean mass is preserved (162). 
CONCLUSION
Obesity is a chronic, low-grate inflammatory disorder associ-
ated with a number of cardiovascular and metabolic risk factors 
(163). There are complex paracrine and endocrine communica-
tion pathways that in healthy individuals promote homeostasis. 
However, when challenged in conditions such as obesity, by 
modulations of genes or environment, these networks can be 
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altered in ways that result in deleterious changes to both the 
cardiovascular system and metabolism that ultimately reduce 
life span (Fig. 1). It therefore comes as no surprise that CVD is 
more frequent in subjects with obesity. Moreover, when BMI 
is ≥ 30 kg/m2, mortality rates from all causes, and especially 
CVD, are increased by 50 to 100 % (68). With an increasing 
incidence of obesity, it is important that we not only understand 
the problems associated with excess weight but we strive to 
identify the underlying molecular mechanisms and ways to 
prevent further increases. There is strong evidence that weight 
loss in overweight and obese individuals reduces risk factors 
for diabetes and CVD. This includes a reduction in deleterious 
circulating adipokines and a possible increase of beneficial
adipokines such as adiponectin, IL-10, and NGF (84 and 
references therein). Although there have been no prospective 
trials to convincingly show changes in mortality with weight 
loss in obese patients, it is anticipated that a reduction in risk 
factors would predict a reduced incidence of CVD, and perhaps 
CVD-related mortality. Thus, although the influence of obesity
on all cause and CVD-related mortality remains controversial 
(38), there is a necessary concern for our younger populations 
with decades of obesity ahead of them.
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